Preventive and therapeutic strategies in critically ill patients with highly resistant bacteriaMatteo Bassetti, Garyphallia Poulakou, Jan J. De Waele et al.|Intensive Care Medicine|2015Cited by 182
Lung penetration, bronchopulmonary pharmacokinetic/pharmacodynamic profile and safety of 3 g of ceftolozane/tazobactam administered to ventilated, critically ill patients with pneumoniaLuzelena Caro, Elizabeth G. Rhee, David P. Nicolau et al.|Journal of Antimicrobial Chemotherapy|2020Cited by 67
<i>In Vivo</i> Efficacy of Meropenem with a Novel Non-β-Lactam–β-Lactamase Inhibitor, Nacubactam, against Gram-Negative Organisms Exhibiting Various Resistance Mechanisms in a Murine Complicated Urinary Tract Infection ModelMarguerite L. Monogue, David P. Nicolau, Sara Giovagnoli et al.|Antimicrobial Agents and Chemotherapy|2018Cited by 55
Meropenem–nacubactam activity against AmpC-overproducing and KPC-expressing Pseudomonas aeruginosa in a neutropenic murine lung infection modelTomefa E. Asempa, David P. Nicolau, Ana Motos et al.|International Journal of Antimicrobial Agents|2019Cited by 37
Pharmacokinetics and Pharmacodynamics of Ceftolozane/Tazobactam in Critically Ill Patients With Augmented Renal ClearanceDavid P. Nicolau, Matthew L. Rizk, Jan J. De Waele et al.|International Journal of Antimicrobial Agents|2021Cited by 34